Model for diabetic patients | Treatments | RD | LL. | UL | NNT | LL | UL |
 ATE | RAAS1 vs non-RAAS | −0.0100 | −0.0445 | 0.0246 | −100.3 | −447.6 | 247.0 |
 | RAAS2 vs non-RAAS | −0.0712 | −0.0878 | −0.0547 | −14.0 | −17.3 | −10.8 |
 |  | Risk | LL | UL | RR | LL | UL |
 POM | Non-RAAS | 0.1999 | 0.1917 | 0.2082 | 1 |  |  |
 | RAAS1 | 0.1899 | 0.0779 | 0.1905 | 0.950 | 0.778 | 1.123 |
 | RAAS2 | 0.1287 | 0.1139 | 0.1435 | 0.644 | 0.567 | 0.721 |
Model for non-diabetic patients | Treatments | RD | LL. | UL | NNT | LL | UL |
 ATE | RAAS1 vs non-RAAS | −0.0205 | 0–.0863 | 0.0453 | −48.7 | −204.9 | 107.5 |
 | RAAS2 vs non-RAAS | −0.0674 | −0.1216 | −0.0132 | −14.8 | −26. 8 | −2.9 |
 |  | Risk | LL | UL | RR | LL | UL |
 POM | Non-RAAS | 0.1812 | 0.1745 | 0.1879 | 1 |  |  |
 | RAAS1 | 0.1607 | 0.0949 | 0.2265 | 0.887 | 0.523 | 1.250 |
 | RAAS2 | 0.1139 | 0.0598 | 0.1679 | 0.628 | 0.3301 | 0.926 |